A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants
Completed · Phase 1 · NCT06627088
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $186,151
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Tested
- LY4100511 (DC-853) (drug), [14C]-LY4100511 (DC-853) Administered oral dose (drug), LY4100511 (DC-853) (drug), [14C]-LY4100511 (DC-853) (drug)
- Dates
- Started 2024-08-23; completion 2024-12-31
- Results posted
- Not yet
The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \[14C\]-LY4100511, LY4100511, and TRA.
From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $186,151 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc $186,151
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.